Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease Obefazimod Crohn's Disease (CD) IND filed with the FDA in December 2023 and cleared to proceedIn alignment with FDA feedback, Abivax to modify CD trial design and conduct dose ranging Phase 2b clinical trialStart of patient enrollment planned for Q3 202412-week induction data read-out expected in 2H 2026 PARIS, France, February 2, 2024, 8:30 a.m. CET – Abivax SA ((Euronext Paris &amp, ...